AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
Log in

NASDAQ:AXGN - AxoGen Stock Price, Forecast & News

$14.94
+0.16 (+1.08 %)
(As of 02/20/2020 04:00 PM ET)
Today's Range
$14.75
Now: $14.94
$15.06
50-Day Range
$12.24
MA: $14.14
$17.33
52-Week Range
$10.91
Now: $14.94
$25.84
Volume364,413 shs
Average Volume329,550 shs
Market Capitalization$589.67 million
P/E RatioN/A
Dividend YieldN/A
Beta0.33
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXGN
CUSIPN/A
Phone386-462-6800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$83.94 million
Book Value$3.84 per share

Profitability

Net Income$-22,400,000.00

Miscellaneous

EmployeesN/A
Market Cap$589.67 million
Next Earnings Date2/24/2020 (Confirmed)
OptionableOptionable

Receive AXGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.


AxoGen (NASDAQ:AXGN) Frequently Asked Questions

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

How were AxoGen's earnings last quarter?

AxoGen, Inc (NASDAQ:AXGN) posted its earnings results on Monday, October, 29th. The medical equipment provider reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). The medical equipment provider had revenue of $22.66 million for the quarter, compared to analyst estimates of $22.52 million. AxoGen had a negative return on equity of 17.82% and a negative net margin of 26.79%. AxoGen's revenue for the quarter was up 41.2% compared to the same quarter last year. During the same period last year, the company earned ($0.04) earnings per share. View AxoGen's Earnings History.

When is AxoGen's next earnings date?

AxoGen is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for AxoGen.

How can I listen to AxoGen's earnings call?

AxoGen will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $106.6 million, compared to the consensus revenue estimate of $107.76 million.

What price target have analysts set for AXGN?

5 brokerages have issued twelve-month price objectives for AxoGen's stock. Their forecasts range from $21.00 to $30.00. On average, they expect AxoGen's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 67.3% from the stock's current price. View Analyst Price Targets for AxoGen.

What is the consensus analysts' recommendation for AxoGen?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AxoGen.

Has AxoGen been receiving favorable news coverage?

Media coverage about AXGN stock has trended somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. AxoGen earned a daily sentiment score of -1.9 on InfoTrie's scale. They also gave press coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for AxoGen.

Are investors shorting AxoGen?

AxoGen saw a decline in short interest in January. As of January 31st, there was short interest totalling 1,660,000 shares, a decline of 18.6% from the January 15th total of 2,040,000 shares. Based on an average trading volume of 355,000 shares, the short-interest ratio is presently 4.7 days. Approximately 4.7% of the company's shares are short sold. View AxoGen's Current Options Chain.

Who are some of AxoGen's key competitors?

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Intelsat (I), Exelixis (EXEL), Advanced Micro Devices (AMD), Xilinx (XLNX), Bank of America (BAC), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Micron Technology (MU), Amarin (AMRN) and NVIDIA (NVDA).

Who are AxoGen's key executives?

AxoGen's management team includes the folowing people:
  • Ms. Karen Zaderej, Chairman, Pres & CEO (Age 57)
  • Mr. Peter J. Mariani, Chief Financial Officer (Age 55)
  • Mr. Gregory G. Freitag Esq., J.D., CPA, Gen. Counsel & Director (Age 57)
  • Mr. Michael Donovan, VP of Operations (Age 54)
  • Ms. Kaila Paige Krum, VP of Investor Relations & Corp. Devel.

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (15.15%), Baillie Gifford & Co. (2.61%), State Street Corp (2.55%), William Blair Investment Management LLC (2.34%), Bank of New York Mellon Corp (2.22%) and Bank of America Corp DE (2.21%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Daniel Pietrzak, David K Hansen, Gregory Gene Freitag, Isabelle Billet, Jamie Mark Grooms, Karen L Zaderej, Michael Patrick Donovan, Quentin S Blackford and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.

Which institutional investors are selling AxoGen stock?

AXGN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Bank of New York Mellon Corp, Renaissance Technologies LLC, Peregrine Capital Management LLC, Goldman Sachs Group Inc., Penn Capital Management Co. Inc., Perkins Capital Management Inc. and BerganKDV Wealth Management LLC. Company insiders that have sold AxoGen company stock in the last year include David K Hansen and Michael Patrick Donovan. View Insider Buying and Selling for AxoGen.

Which institutional investors are buying AxoGen stock?

AXGN stock was purchased by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, William Blair Investment Management LLC, Point72 Asset Management L.P., Bank of America Corp DE, Bank of Montreal Can, Jacobs Levy Equity Management Inc., Granite Investment Partners LLC and Baillie Gifford & Co.. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, Daniel Pietrzak, Isabelle Billet, Karen L Zaderej and Quentin S Blackford. View Insider Buying and Selling for AxoGen.

How do I buy shares of AxoGen?

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $14.94.

How big of a company is AxoGen?

AxoGen has a market capitalization of $589.67 million and generates $83.94 million in revenue each year. The medical equipment provider earns $-22,400,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. View Additional Information About AxoGen.

What is AxoGen's official website?

The official website for AxoGen is http://www.axogeninc.com/.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]


MarketBeat Community Rating for AxoGen (NASDAQ AXGN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  398 (Thanks for Voting!)
Underperform Votes:  286 (Thanks for Voting!)
Total Votes:  684
MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe AXGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel